What is it about?
The immune system has the ability to recognize and destroy cancer cells. Normally, T cells do this when cancer cells display peptides on an MHC molecule. Many cancers evade the immune system by no longer displaying these peptides or an MHC molecule. In this study, we discovered an unexpected way that activated T cells can kill certain acute myeloid leukemia (AML) cells even with MHC loss. We found that this process depends on a protein called CD64 and requires the T-cell receptor in a way that differs from the traditional model of immune recognition.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
In this study, we demonstrate that T cells can kill acute myeloid leukemia (AML) cells in an MHC-independent manner that still requires an intact TCR. This finding is dependent on expression of CD64 by target cells and reveals a distinct form of CD64-dependent, pMHC-independent, TCR-dependent killing by CTLs. This discovery expands our understanding of how T cells can fight cancer and could help guide the development of future immune-based treatments for leukemia and other blood cancers.
Perspectives
Working on this project was a joyful team-effort with many unexpected findings, we hope the readers find it interesting.
KAPIL Saxena
Read the Original
This page is a summary of: CD64 enables TCR-dependent, MHC-independent CTL cytotoxicity of AML cells, Proceedings of the National Academy of Sciences, July 2026, Proceedings of the National Academy of Sciences,
DOI: 10.1073/pnas.2601232123.
You can read the full text:
Contributors
The following have contributed to this page
